Latest Conference Articles

February 7th 2021, 7:25pm

PER® Winter Lung Cancer Conference

Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.

February 7th 2021, 5:25pm

PER® Winter Lung Cancer Conference

Mark A. Socinski, MD, discusses the nuances of the PACIFIC trial and ongoing research with durvalumab that could extend the reach of immunotherapy in early-stage lung cancer.

February 6th 2021, 7:15pm

PER® Winter Lung Cancer Conference

Over the past 2 decades, the field of EGFR-mutated non–small cell lung cancer has grown tremendously, but the influx of data and the recent regulatory approval of adjuvant osimertinib have raised several important questions to be addressed to ensure that the optimal treatment approach is utilized.

February 6th 2021, 6:30pm

PER® Winter Lung Cancer Conference

Rogerio C. Lilenbaum, MD, discusses some of the key clinical issues facing the lung cancer field, the role of genomic testing and multidisciplinary care, and the challenges that arose with telemedicine during the coronavirus disease 2019 pandemic.

February 6th 2021, 5:55pm

PER® Winter Lung Cancer Conference

In the quest for scientific purity, one should not lose sight of the meaningful end points that can make a difference in patients’ daily lives.

February 6th 2021, 5:00pm

PER® Winter Lung Cancer Conference

Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.

February 6th 2021, 5:00pm

PER® Winter Lung Cancer Conference

Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.

February 6th 2021, 12:00am

PER® Winter Lung Cancer Conference

Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.

February 6th 2021, 12:00am

PER® Winter Lung Cancer Conference

Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.

January 31st 2021, 7:25pm

IASLC World Conference on Lung Cancer

January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.

January 31st 2021, 6:10pm

IASLC World Conference on Lung Cancer

January 31, 2021 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free survival for patients with extensive stage small cell lung cancer.

January 31st 2021, 5:52pm

IASLC World Conference on Lung Cancer

Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.

January 31st 2021, 5:18pm

IASLC World Conference on Lung Cancer

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

January 31st 2021, 5:14pm

IASLC World Conference on Lung Cancer

Martin Reck, MD, PhD, discusses the efficacy of maintenance atezolizumab in patients with extensive-stage small cell lung cancer.

January 30th 2021, 8:38pm

IASLC World Conference on Lung Cancer

January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.

January 30th 2021, 7:30pm

IASLC World Conference on Lung Cancer

January 30, 2021 - Data from the phase 3 CONFIRM trial support single-agent nivolumab as an effective treatment approach for patients with previously treated malignant mesothelioma.

January 30th 2021, 5:33pm

IASLC World Conference on Lung Cancer

Stephen Liu, MD, discusses emerging research on antibody–drug conjugate in non–small cell lung cancer that were presented during the 2020 World Conference on Lung Cancer.

January 30th 2021, 3:32pm

IASLC World Conference on Lung Cancer

Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

January 30th 2021, 2:17am

IASLC World Conference on Lung Cancer

January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.

January 30th 2021, 12:45am

IASLC World Conference on Lung Cancer

January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.